Macrogenics (MGNX) Free Cash Flow (2012 - 2026)
Macrogenics (MGNX) posted quarterly Free Cash Flow of -$36.1 million for Q1 2026, up 23.61% year-over-year from -$29.2 million in Q1 2025, and down 183.97% quarter-over-quarter from $43.0 million in Q4 2025.
Macrogenics (MGNX) Free Cash Flow (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Free Cash Flow for 15 consecutive years, with -$36.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 23.61% year-over-year to -$36.1 million; the TTM figure through Mar 2026 stood at -$69.9 million (up 4.76% YoY), while the FY2025 annual figure was -$81.1 million, down 12.51% from the prior year.
- Free Cash Flow fell to -$36.1 million in Q1 2026 per MGNX's latest filing, from $43.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $57.1 million in Q3 2024 and bottomed at -$59.1 million in Q1 2022.
- Historically, Free Cash Flow has averaged -$21.1 million across 5 years, with a median of -$35.7 million in 2023.
- On a YoY basis, Free Cash Flow climbed as much as 259.78% in 2024 and fell as far as 1631.68% in 2024.
- Macrogenics' Free Cash Flow stood at $28.9 million in 2022, then slumped by 194.71% to -$27.4 million in 2023, then sank by 42.44% to -$39.0 million in 2024, then soared by 210.11% to $43.0 million in 2025, then slumped by 183.97% to -$36.1 million in 2026.
- Business Quant data shows MGNX's Free Cash Flow at -$36.1 million in Q1 2026, $43.0 million in Q4 2025, and -$30.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -36.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.09 Mn |
| Mar 31, 2026 | -36.09 Mn |
| Dec 31, 2025 | 42.97 Mn |
| Dec 31, 2025 | 42.97 Mn |
| Sep 30, 2025 | -30.16 Mn |
| Sep 30, 2025 | -30.16 Mn |
| Jun 30, 2025 | -46.67 Mn |
| Jun 30, 2025 | -46.67 Mn |
| Mar 31, 2025 | -47.24 Mn |
| Mar 31, 2025 | -47.24 Mn |
| Dec 31, 2024 | -39.03 Mn |
| Dec 31, 2024 | -39.03 Mn |
| Sep 30, 2024 | 57.11 Mn |
| Sep 30, 2024 | 57.11 Mn |
| Jun 30, 2024 | -44.28 Mn |
| Jun 30, 2024 | -44.28 Mn |
| Mar 31, 2024 | -45.89 Mn |
| Mar 31, 2024 | -45.89 Mn |
| Dec 31, 2023 | -27.40 Mn |
| Dec 31, 2023 | -27.40 Mn |